Rexahn Pharma (RNN) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
Rexahn Pharmaceuticals Reports Second Quarter 2016 Financial and Operational Results
August 8, 2016 9:01 AM EDTROCKVILLE, Md., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced financial results for the second quarter ended June 30, 2016 and provided an update on the Companys clinical development programs.
Important clinical data from each of our novel oncology programs were presented at two premier oncology-focused medical conferences during the second quarter, said Peter D. Suzdak, Ph.D., Chief Executive Officer. We are very pleased with the accumulating data from these studies, which... More
